The development of medicines based solely or in part on glucagon-like peptide-1 (GLP-1) action, herein referred to as GLP-1 medicines, has transformed the treatment options for people with type 2 diabetes (T2D) who are unable to achieve sufficient glucose control with existing therapies. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.